Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675721 | 0.97 | HSD11B1 (0.44) | HSD11B1TP53LMNAMAPTHPGD | |
| SCHEMBL4514386 | 0.88 | HSD11B1 (0.46) | HSD11B1TP53LMNAHPGDKDM4E | |
| SCHEMBL4521181 | 0.88 | HSD11B1 (0.46) | HSD11B1TP53LMNAMAPTHPGD | |
| SCHEMBL4525800 | 0.87 | HSD11B1 (0.47) | HSD11B1TP53LMNAHPGDKDM4E | |
| SCHEMBL13674511 | 0.87 | HSD11B1 (0.47) | HSD11B1TP53LMNAMAPTHPGD | |
| SCHEMBL4513272 | 0.87 | HSD11B1 (0.54) | HSD11B1HRH3 | |
| SCHEMBL4516252 | 0.86 | HSD11B1 (0.55) | HSD11B1TP53LMNAHPGDKDM4E | |
| SCHEMBL4520465 | 0.86 | HPGD (0.48) | HSD11B1TP53HPGDKDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL4514348 | 0.86 | HSD11B1 (0.46) | HSD11B1TP53LMNAHPGDKDM4E | |
| SCHEMBL4514972 | 0.85 | HSD11B1 (0.44) | HSD11B1TP53LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885TP53 3134/4885LMNA 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.